.
Fast-Track Your Due Diligence
Fast Delivery of Investor
Updates and Support
.
Details
Cell and Gene Therapy TAM
30.8B NZD in 2022
155.1B NZD by 2030
22.4% CAGR
Lentiviral Vector Manufacture Market
2.4B NZD TAM
1.3B NZD SAM
11.9% CAGR
Bridge Round
Raising NZD 3.5M in Q3/23

- Scaling production capacity from preclinical to clinical-grade.
- Improving production technology and processes.
- Developing and securing intellectual property during the bridge round.

- Ensuring regulatory compliance
with all requirements. - Securing manufacturing contracts with biotech and pharmaceutical companies
- Increasing capacity
with strategic alliances and partnerships.
Investing in New Zealand
There are many benefits for choosing New Zealand.
- Highly skilled workforce
- Supportive government
- Favorable regulatory environment
- A strong economy
- An attractive place to work
Overall, New Zealand is an excellent location for biotech CDMOs. The country has a number of advantages that make it an attractive option for companies to develop and manufacture high value biological products.
Trans-Pacific Partnership
New Zealand is a member of the Trans-Pacific Partnership (TPP). Some of our benefits are.
- Reduced tariffs among member countries
- Enhanced intellectual property rights
- Regulatory coherence streamline regulations among member countries
- Easier access to markets of all member countries
- Supply chain efficiency
- The TPP includes provisions that protect foreign investments
- High labor and environmental standards
Experienced Leadership
Benefit from the expertise of an experienced leadership team. BioViros is backed by Bridgewest Group.

Lab Team

Hannah Pearce, Ph.D.
Biotech Development Scientist

Sofia Grey
Process Development Assistant

Isabella Lovalvo
Student Intern - Berkeley, California

Ellie Torbati, Ph.D.
Biotech Research Scientist

Management

Marina Rajic, Ph.D.
Founder & CEO

Tom VanCott, Ph.D.
Director, Chairman

Saum Vahdat
Director

John Robson
Director

Advisors

Farzad Haerizadeh, Ph.D.
Scientific Advisor

Stephen Chang, Ph.D.
Scientific Advisor

Rick Hancock
Strategic Advisor
Consider BioViros as Investment
Action Required
Fund raising for the bridge round will end in August 2023. Get the info.